Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Unknown 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Multiple Myeloma 85Recurrence 10Lymphoma 8Leukemia, Myeloid, Acute 6Immunoglobulin Light-chain Amyloidosis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Mantle-Cell 5Waldenstrom Macroglobulinemia 4Neoplasms, Plasma Cell 3Hematologic Neoplasms 3Plasmacytoma 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Biphenotypic, Acute 2Carcinoma, Renal Cell 2Breast Neoplasms 2Amyloidosis 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Proteostasis Deficiencies 1Plasmablastic Lymphoma 1POEMS Syndrome 1Neurofibrosarcoma 1

Interventions

Rituximab 226Cyclophosphamide 202fludarabine phosphate 108Peripheral Blood Stem Cell Transplantation 103Filgrastim 87Etoposide 76Cytarabine 70ibrutinib 68Mycophenolic Acid 67Bortezomib 66Whole-Body Irradiation 63Cyclosporine 63Melphalan 59Lenalidomide 59Bendamustine Hydrochloride 58Vincristine 53Radiotherapy 53fludarabine 52Tacrolimus 50Doxorubicin 48Busulfan 48Methotrexate 47Antilymphocyte Serum 42Prednisone 41Carmustine 40Dexamethasone 38Granulocyte Colony-Stimulating Factor 33venetoclax 32acalabrutinib 31zanubrutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × ixazomib × Clear all
NCT02339922 2026-03-05

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

University of Washington

Phase 2 Active not recruiting
33 enrolled 16 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04047797 2025-04-20

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 10 charts
Lymphoid

Lymphoma, Mantle-Cell

NCT03323151 2024-01-18

PrE0404

PrECOG, LLC.

Phase 1/2 Completed
43 enrolled 21 charts
Lymphoid

Lymphoma, Mantle-Cell

NCT03616782 2023-10-06

Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)

Kosin University Gospel Hospital

Phase 2 Unknown
98 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT02632396 2023-05-09

Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission

Emory University

Phase 1/2 Unknown
12 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡